| scholarly article | Q13442814 |
| P50 | author | Alicia M Pickrell | Q56418813 |
| Milena Pinto | Q56418816 | ||
| P2093 | author name string | Carlos T Moraes | |
| Aline Hida | |||
| P2860 | cites work | PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease | Q24597726 |
| Sequence and organization of the human mitochondrial genome | Q27860659 | ||
| Analyzing real-time PCR data by the comparative C(T) method | Q28131831 | ||
| Chronic systemic pesticide exposure reproduces features of Parkinson's disease | Q29614763 | ||
| High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease | Q29619113 | ||
| Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism | Q31141329 | ||
| Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease | Q33789328 | ||
| Double-strand breaks of mouse muscle mtDNA promote large deletions similar to multiple mtDNA deletions in humans | Q34062921 | ||
| Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline | Q34528059 | ||
| Retracted: Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging | Q34613904 | ||
| Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease | Q34682391 | ||
| Disease model: Parkinson's disease. | Q35203031 | ||
| The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions | Q35219902 | ||
| Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons | Q35611727 | ||
| Release of newly synthesized dopamine from dopamine-containing terminals in the striatum of the rat. | Q36450559 | ||
| Behavioral models of Parkinson's disease in rodents: a new look at an old problem | Q36531775 | ||
| RETRACTED: Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype | Q37036533 | ||
| Genetic mouse models of Parkinson's disease The state of the art. | Q37796009 | ||
| Presynaptic control of serotonin on striatal dopamine function | Q37800812 | ||
| Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease | Q40761854 | ||
| Disease-specific patterns of locus coeruleus cell loss | Q41102223 | ||
| Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disea | Q41158228 | ||
| Mitochondrial complex I deficiency in Parkinson's disease | Q41821730 | ||
| Nature of mitochondrial DNA deletions in substantia nigra neurons | Q43058638 | ||
| Mechanisms of formation and accumulation of mitochondrial DNA deletions in aging neurons | Q43076986 | ||
| Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease | Q43232740 | ||
| Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice | Q48268769 | ||
| Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium | Q48349404 | ||
| A review of Lewy body disease, an emerging concept of cortical dementia | Q48410265 | ||
| Dopamine scales performance in the absence of new learning. | Q48430480 | ||
| Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons | Q48588748 | ||
| Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion | Q48725191 | ||
| Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic | Q60308143 | ||
| Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting | Q73919702 | ||
| Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy as α-Synucleinopathies | Q83405808 | ||
| P4510 | describes a project that uses | mitochondrial DNA | Q27075 |
| P433 | issue | 48 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| mitochondrial DNA | Q27075 | ||
| dopamine | Q170304 | ||
| striatum | Q1319792 | ||
| DNA damage | Q5205747 | ||
| P304 | page(s) | 17649-17658 | |
| P577 | publication date | 2011-11-01 | |
| P1433 | published in | Journal of Neuroscience | Q1709864 |
| P1476 | title | Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease | |
| P478 | volume | 31 |
| Q101410046 | A transition to degeneration triggered by oxidative stress in degenerative disorders |
| Q91906802 | Abnormal Mitochondria in a Non-human Primate Model of MPTP-induced Parkinson's Disease: Drp1 and CDK5/p25 Signaling |
| Q34864555 | Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms |
| Q27021628 | Ageing and Parkinson's disease: why is advancing age the biggest risk factor? |
| Q89676333 | Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models |
| Q36929398 | Behavioral and metabolic characterization of heterozygous and homozygous POLG mutator mice |
| Q38963019 | Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target? |
| Q35153576 | Compensatory mechanisms in genetic models of neurodegeneration: are the mice better than humans? |
| Q35911424 | Cumulative mtDNA damage and mutations contribute to the progressive loss of RGCs in a rat model of glaucoma |
| Q35830757 | Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease |
| Q38605280 | Dissecting the role of Engrailed in adult dopaminergic neurons--Insights into Parkinson disease pathogenesis |
| Q48363359 | Effects of mild running on substantia nigra during early neurodegeneration. |
| Q27305291 | Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress |
| Q38019565 | Engrailed signaling in axon guidance and neuron survival |
| Q34653802 | Exposure to mitochondrial genotoxins and dopaminergic neurodegeneration in Caenorhabditis elegans |
| Q89107257 | Human primitive brain displays negative mitochondrial-nuclear expression correlation of respiratory genes |
| Q60111586 | Ion-Catalyzed Reactive Oxygen Species in Sporadic Models of Parkinson’s Disease |
| Q47313391 | Lack of Parkin anticipates the phenotype and affects mitochondrial morphology and mtDNA levels in a mouse model of Parkinson's Disease |
| Q40231021 | Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease |
| Q36714253 | Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit |
| Q47633073 | Mitochondrial DNA Double-Strand Breaks in Oligodendrocytes Cause Demyelination, Axonal Injury, and CNS Inflammation. |
| Q33608218 | Mitochondrial DNA damage in a mouse model of Alzheimer's disease decreases amyloid beta plaque formation |
| Q34090228 | Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease |
| Q35660977 | Mitochondrial Diseases Part II: Mouse models of OXPHOS deficiencies caused by defects in regulatory factors and other components required for mitochondrial function |
| Q64765404 | Mitochondrial Dysfunction in Parkinson's Disease-Cause or Consequence? |
| Q28280353 | Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease |
| Q38021865 | Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences |
| Q27023750 | Mitochondrial genome changes and neurodegenerative diseases |
| Q48098220 | Mitochondrial retrograde signaling in the nervous system |
| Q36268449 | Mitochondrial retrograde signaling regulates neuronal function |
| Q48199859 | Morinda citrifolia mitigates rotenone-induced striatal neuronal loss in male Sprague-Dawley rats by preventing mitochondrial pathway of intrinsic apoptosis. |
| Q26829851 | Mouse models of Parkinson's disease associated with mitochondrial dysfunction |
| Q36655956 | Parkinson's disease: a complex interplay of mitochondrial DNA alterations and oxidative stress |
| Q38902216 | Parkinson's disease: diagnostic utility of volumetric imaging |
| Q47389506 | Parkinson's disease: experimental models and reality |
| Q33794494 | Pentazocine Protects SN4741 Cells Against MPP+-Induced Cell Damage via Up-Regulation of the Canonical Wnt/β-Catenin Signaling Pathway |
| Q27301100 | Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation |
| Q48374033 | Structural covariance networks of striatum subdivision in patients with Parkinson's disease |
| Q38374332 | The Parkinson Disease Mitochondrial Hypothesis: Where Are We at? |
| Q37467929 | The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism |
| Q38202314 | The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease |
| Q41967848 | The challenge in translating basic research discoveries to treatment of Huntington disease |
| Q37583410 | The impact of mitochondrial DNA and nuclear genes related to mitochondrial functioning on the risk of Parkinson's disease. |
| Q28588745 | The mitochondrial disease associated protein Ndufaf2 is dispensable for Complex-1 assembly but critical for the regulation of oxidative stress |
| Q35152954 | The role of mitochondrial DNA mutation on neurodegenerative diseases |
| Q34758002 | The use of mitochondria-targeted endonucleases to manipulate mtDNA |
| Q93140140 | Voluntary exercise normalizes the proteomic landscape in muscle and brain and improves the phenotype of progeroid mice |
| Q26778937 | Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease |
Search more.